Ticker News
$CTSO News
Stored TradersLink news articles and press-release context for this ticker. Discord alerts link into these article pages when full article text is available.
Published Articles
Latest saved alerts
Real-world data: CytoSorb cuts severe bleeding in CABG patients on ticagrelor; FDA pre-sub meetings advance DrugSorb‑ATR plans
CytoSorbents (CTSO) reported a patient-level matched real-world analysis of 587 urgent CABG patients on ticagrelor showing intraoperative CytoSorb use was associated with a 37% relative reduction in severe perioperative bleeding (BARC‑4: 21.8% vs 34.5%) and an NNT of 8, plus reductions in 24‑hr chest tube drainage and RBC transfusions with no serious device‑related adverse events. The company said the data—presented at ESC 2026—will be a core component of an expanded De Novo submission for DrugSorb‑ATR under FDA Breakthrough designation and that recent FDA pre-submission meetings were constructive for parallel ticagrelor and DOAC applications, with a planned new De Novo submission in early 2027.
CytoSorbents (CTSO) to present at Life Sciences Forum June 24; investor 1-on-1s June 30
CytoSorbents (CTSO) said CEO Phillip Chan will present at the VirtualInvestorConferences Life Sciences Forum on June 24 with a Zacks-hosted Q&A including CFO Peter Mariani, and management will hold one-on-one investor meetings on June 30 to provide an update. The appearances are an investor-access catalyst where management is likely to discuss corporate and regulatory progress (the company holds two FDA Breakthrough Device designations for DrugSorb-ATR) and its target to reach cash-flow break-even in H2 2026; no new clinical data, approvals, or financial results were disclosed.
CTSO CFO buys 100,000 shares at $0.44, now owns 638,113 shares
CTSO filed SEC Form 4. Mariani reported an open-market purchase of 100,000 common shares on 06/15/2026 at a weighted average price of $0.44 (trades ranged $0.40–$0.45). After the purchase his total beneficial ownership is reported as 638,113 shares, which includes 216,613 directly owned shares and several RSU grants that vest on service dates or upon a change in control.